Stocks › MDXG
MiMedx MDXG
US equityMarket cap rank #3671
$3.31 +$0.03 (+0.91%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $3.31 0.00%
Open$3.25
Prev close$3.28
Day range$3.23 – $3.39
Volume1.11M
Market cap$483.01M
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±9.3%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+39.4%
Worst reaction-13.0%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 28 Oct 2026 | After Market | – | +0.51% | – |
| 2026/Q2 | 29 Jul 2026 | After Market | – | +0.95% | – |
| 2026/Q1 | 29 Apr 2026 | After Market | – | +8.91% | – |
| 2025/Q4 | 25 Feb 2026 | After Market | ±15.9% | -6.44% | Within range |
| 2025/Q3 | 29 Oct 2025 | After Market | ±17.0% | +2.92% | Within range |
| 2025/Q2 | 30 Jul 2025 | After Market | ±22.0% | +10.28% | Within range |
| 2025/Q1 | 30 Apr 2025 | After Market | ±21.7% | -8.14% | Within range |
| 2024/Q4 | 26 Feb 2025 | After Market | ±30.0% | +1.62% | Within range |
| 2024/Q3 | 30 Oct 2024 | After Market | ±14.9% | +20.39% | Bigger than priced |
| 2024/Q2 | 31 Jul 2024 | After Market | ±19.1% | -10.34% | Within range |
| 2024/Q1 | 30 Apr 2024 | After Market | ±26.0% | +18.67% | Within range |
| 2023/Q4 | 28 Feb 2024 | After Market | ±21.2% | -0.49% | Within range |
| 2023/Q3 | 30 Oct 2023 | After Market | ±25.3% | +3.80% | Within range |
| 2023/Q2 | 1 Aug 2023 | After Market | ±14.5% | -2.90% | Within range |
| 2023/Q1 | 2 May 2023 | After Market | ±31.2% | +39.37% | Bigger than priced |
| 2022/Q4 | 28 Feb 2023 | After Market | ±22.2% | -12.99% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$62.28M-45.2% YoY
Operating profit-$11.70M-152.7% YoY
Net profit-$8.68M-151.8% YoY
Diluted EPS-$0.06-154.5% YoY
Free cash flow-$1.14M-104.5% YoY
Operating cash flow$3.92M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin77.3%
Operating margin-8.3%
Net margin-6.3%
Return on equity-8.5%
Return on assets-6.6%
Return on invested capital-8.5%
Current ratio4.35
Liabilities / assets20.2%
Cash & investments$120.79M
Net cash (debt)$120.79M
Free cash flow / sales5.9%
No comments yet — be the first to weigh in on MDXG.
Sign in to join the discussion.